Literature DB >> 1994484

Loss of maternal measles antibody in black South African infants in the first year of life--implications for age of vaccination.

P Kiepiela1, H M Coovadia, W E Loening, P Coward, S S Abdool Karim.   

Abstract

In order to investigate the feasibility of measles vaccination before the age of 9 months the duration of passive immunity against measles was estimated by conducting a longitudinal study of measles antibody levels in 20 black neonates delivered at term. Measles serum antibody (IgG) was measured by enzyme-linked immunosorbent assay in the mother at childbirth and on consecutive samples taken from the infants from birth until 9 months of age. Protective measles antibody level was defined as greater than 200 mIU. Unprotective levels were found in 88% (95% confidence interval (CI) 81-99%) of 6-month-old infants, while at 9 months all were susceptible. The mean antibody level was 192 mIU (CI 104-348%) at 4 months; 34 mIU (CI 15-73%) at 6 months and 13 mIU (CI 6-24%) at 9 months of age. Our data support the recent World Health Organisation recommendation to immunise children in developing countries at 6 months with the 'high titre' Edmonston-Zagreb measles vaccine, since most infants in our study had lost passive immunity against measles by this age.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1994484

Source DB:  PubMed          Journal:  S Afr Med J


  3 in total

1.  Measles virus-specific antibody levels in individuals in Argentina who received a one-dose vaccine.

Authors:  Marcelo H Argüelles; Mariana L Orellana; Alejandro A Castello; Guillermo A Villegas; Matilde Masini; Alejandra L Belizan; Silvia González Ayala; Osmar D Vera; Graciela Glikmann
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

2.  Decay of passively acquired maternal antibodies against measles, mumps, and rubella viruses.

Authors:  C Nicoara; K Zäch; D Trachsel; D Germann; L Matter
Journal:  Clin Diagn Lab Immunol       Date:  1999-11

3.  Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months.

Authors:  Maurice A Mufson; Clemente Diaz; Michael Leonardi; Christopher J Harrison; Stanley Grogg; Antonio Carbayo; Simon Carlo-Torres; Robert JeanFreau; Ana Quintero-Del-Rio; Gisele Bautista; Michael Povey; Christopher Da Costa; Ouzama Nicholson; Bruce L Innis
Journal:  J Pediatric Infect Dis Soc       Date:  2014-08-07       Impact factor: 3.164

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.